These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 22957712)

  • 1. Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors.
    Okamoto I; Arao T; Miyazaki M; Satoh T; Okamoto K; Tsunoda T; Nishio K; Nakagawa K
    Cancer Sci; 2012 Dec; 103(12):2135-8. PubMed ID: 22957712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor.
    Hayashi H; Kurata T; Fujisaka Y; Kawakami H; Tanaka K; Okabe T; Takeda M; Satoh T; Yoshida K; Tsunoda T; Arao T; Nishio K; Nakagawa K
    Cancer Sci; 2013 Jan; 104(1):98-104. PubMed ID: 23020774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of combination therapy of gemcitabine plus anti-angiogenic vaccination of elpamotide in patients with advanced or recurrent biliary tract cancer.
    Matsuyama M; Ishii H; Furuse J; Ohkawa S; Maguchi H; Mizuno N; Yamaguchi T; Ioka T; Ajiki T; Ikeda M; Hakamada K; Yamamoto M; Yamaue H; Eguchi K; Ichikawa W; Miyazaki M; Ohashi Y; Sasaki Y
    Invest New Drugs; 2015 Apr; 33(2):490-5. PubMed ID: 25502982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study.
    Yamaue H; Tsunoda T; Tani M; Miyazawa M; Yamao K; Mizuno N; Okusaka T; Ueno H; Boku N; Fukutomi A; Ishii H; Ohkawa S; Furukawa M; Maguchi H; Ikeda M; Togashi Y; Nishio K; Ohashi Y
    Cancer Sci; 2015 Jul; 106(7):883-90. PubMed ID: 25867139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer.
    Masuzawa T; Fujiwara Y; Okada K; Nakamura A; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Kurokawa Y; Osawa R; Takeda K; Yoshida K; Tsunoda T; Nakamura Y; Mori M; Doki Y
    Int J Oncol; 2012 Oct; 41(4):1297-304. PubMed ID: 22842485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of a personalized peptide vaccine for patients positive for human leukocyte antigen--A24 with recurrent or progressive glioblastoma multiforme.
    Terasaki M; Shibui S; Narita Y; Fujimaki T; Aoki T; Kajiwara K; Sawamura Y; Kurisu K; Mineta T; Yamada A; Itoh K
    J Clin Oncol; 2011 Jan; 29(3):337-44. PubMed ID: 21149665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer.
    Sundar R; Rha SY; Yamaue H; Katsuda M; Kono K; Kim HS; Kim C; Mimura K; Kua LF; Yong WP
    BMC Cancer; 2018 Mar; 18(1):332. PubMed ID: 29587677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome.
    Hazama S; Nakamura Y; Takenouchi H; Suzuki N; Tsunedomi R; Inoue Y; Tokuhisa Y; Iizuka N; Yoshino S; Takeda K; Shinozaki H; Kamiya A; Furukawa H; Oka M
    J Transl Med; 2014 Mar; 12():63. PubMed ID: 24612787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer.
    Miyazawa M; Ohsawa R; Tsunoda T; Hirono S; Kawai M; Tani M; Nakamura Y; Yamaue H
    Cancer Sci; 2010 Feb; 101(2):433-9. PubMed ID: 19930156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I clinical trial of a five-peptide cancer vaccine combined with cyclophosphamide in advanced solid tumors.
    Murahashi M; Hijikata Y; Yamada K; Tanaka Y; Kishimoto J; Inoue H; Marumoto T; Takahashi A; Okazaki T; Takeda K; Hirakawa M; Fujii H; Okano S; Morita M; Baba E; Mizumoto K; Maehara Y; Tanaka M; Akashi K; Nakanishi Y; Yoshida K; Tsunoda T; Tamura K; Nakamura Y; Tani K
    Clin Immunol; 2016 May; 166-167():48-58. PubMed ID: 27072896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer.
    Shindo Y; Hazama S; Suzuki N; Iguchi H; Uesugi K; Tanaka H; Aruga A; Hatori T; Ishizaki H; Umeda Y; Fujiwara T; Ikemoto T; Shimada M; Yoshimatsu K; Takenouchi H; Matsui H; Kanekiyo S; Iida M; Koki Y; Arima H; Furukawa H; Ueno T; Yoshino S; Fujita T; Kawakami Y; Nakamura Y; Oka M; Nagano H
    J Exp Clin Cancer Res; 2017 Feb; 36(1):36. PubMed ID: 28241889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
    Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
    Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I clinical study of a cocktail vaccine of Wilms' tumor 1 (WT1) HLA class I and II peptides for recurrent malignant glioma.
    Tsuboi A; Hashimoto N; Fujiki F; Morimoto S; Kagawa N; Nakajima H; Hosen N; Nishida S; Nakata J; Morita S; Sakamoto J; Oji Y; Oka Y; Sugiyama H
    Cancer Immunol Immunother; 2019 Feb; 68(2):331-340. PubMed ID: 30430205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple therapeutic peptide vaccines for patients with advanced gastric cancer.
    Fujiwara Y; Okada K; Omori T; Sugimura K; Miyata H; Ohue M; Kobayashi S; Takahashi H; Nakano H; Mochizuki C; Shimizu K; Yano M; Nakamura Y; Mori M; Doki Y
    Int J Oncol; 2017 May; 50(5):1655-1662. PubMed ID: 28393243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I/II study of cancer peptide vaccine S-288310 in patients with advanced urothelial carcinoma of the bladder.
    Obara W; Eto M; Mimata H; Kohri K; Mitsuhata N; Miura I; Shuin T; Miki T; Koie T; Fujimoto H; Minami K; Enomoto Y; Nasu T; Yoshida T; Fuse H; Hara I; Kawaguchi K; Arimura A; Fujioka T
    Ann Oncol; 2017 Apr; 28(4):798-803. PubMed ID: 27998971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series.
    Tamura R; Morimoto Y; Kosugi K; Sato M; Oishi Y; Ueda R; Kikuchi R; Nagashima H; Hikichi T; Noji S; Kawakami Y; Sasaki H; Yoshida K; Toda M
    BMC Cancer; 2020 Mar; 20(1):196. PubMed ID: 32164575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploratory open-label clinical study to determine the S-588410 cancer peptide vaccine-induced tumor-infiltrating lymphocytes and changes in the tumor microenvironment in esophageal cancer patients.
    Daiko H; Marafioti T; Fujiwara T; Shirakawa Y; Nakatsura T; Kato K; Puccio I; Hikichi T; Yoshimura S; Nakagawa T; Furukawa M; Stoeber K; Nagira M; Ide N; Kojima T
    Cancer Immunol Immunother; 2020 Nov; 69(11):2247-2257. PubMed ID: 32500232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
    Kakimi K; Isobe M; Uenaka A; Wada H; Sato E; Doki Y; Nakajima J; Seto Y; Yamatsuji T; Naomoto Y; Shiraishi K; Takigawa N; Kiura K; Tsuji K; Iwatsuki K; Oka M; Pan L; Hoffman EW; Old LJ; Nakayama E
    Int J Cancer; 2011 Dec; 129(12):2836-46. PubMed ID: 21448901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II Study of Personalized Peptide Vaccination with Both a Hepatitis C Virus-Derived Peptide and Peptides from Tumor-Associated Antigens for the Treatment of HCV-Positive Advanced Hepatocellular Carcinoma Patients.
    Yutani S; Ueshima K; Abe K; Ishiguro A; Eguchi J; Matsueda S; Komatsu N; Shichijo S; Yamada A; Itoh K; Sasada T; Kudo M; Noguchi M
    J Immunol Res; 2015; 2015():473909. PubMed ID: 26539554
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.